Parkinson’s Disease
Parkinson’s disease is a progressive neurological disorder that primarily affects movement. It is named after Dr. James Parkinson, the physician who first described the condition in 1817. Parkinson’s disease develops as a result of the degeneration and loss of dopamine-producing cells in a region of the brain called the substantia nigra.
The exact cause of Parkinson’s disease is still unknown, but it is believed to involve a combination of genetic and environmental factors. There is currently no cure for Parkinson’s disease, but various treatment approaches aim to manage symptoms and improve quality of life. Medications, such as levodopa and dopamine agonists, can help replenish dopamine levels or mimic its effects. Physical therapy, occupational therapy, and speech therapy can assist with mobility, daily activities, and communication. In some cases, deep brain stimulation (DBS) surgery may be recommended to alleviate symptoms.
This magazine contains content which is gathered, validated, categorized, and supplied using a novel big data cyberinfrastructure technology that continually learns about Parkinson’s Disease.
-
Publication date: Jul 06, 2026 Essential tremor (ET) is a prevalent movement disorder in which ...
-
Antisense Oligonucleotide Tofersen Distribution in the Central Nervous System of SOD1-ALS Autopsy Tissue Donors.
Publication date: Jul 06, 2026 Tofersen is a disease-modifying antisense oligonucleotide therapeutic for people living ... -
Lactate dynamics in Parkinson’s disease: striatal circuit vulnerability, biomarker potential, and therapeutic windows.
Publication date: Jul 06, 2026 Lactate is a mobile carbon substrate, extracellular signal, and candidate ... -
Association of serum homocysteine, folate, and vitamin B₁₂ levels with cognitive function in levodopa-naïve patients with Parkinson’s disease and mild cognitive impairment.
Publication date: Jul 07, 2026 The aim of this study was to examine changes in ... -
Combined Effects of Mutation and Ionic Strength on α-Synuclein Reveal Generic Features of Aggregation-Prone Monomeric States.
Publication date: Jul 07, 2026 α-Synuclein (αS) is a highly charged, intrinsically disordered protein (IDP) ... -
Schizophrenia and disordered sensorimotor control: challenges, mechanisms and opportunities.
Publication date: Jul 07, 2026 Schizophrenia is a common and often disabling neuropsychiatric condition. Whilst ... -
Actigraphy Meets AI: A Digital Biomarker for Parkinson’s Disease and Isolated REM Sleep Behaviour Disorder.
Publication date: Jul 07, 2026 Isolated rapid eye movement (REM) sleep behaviour disorder (RBD) is ... -
Ageing-driven gastrointestinal variability in Parkinson’s disease: implications for oral levodopa pharmacokinetics and formulation design.
Publication date: Jul 07, 2026 Parkinson’s disease is a distinctly age-associated neurodegenerative disorder in which ... -
Substantia Nigra Imaging Biomarker Segmentation for Parkinson’s Disease Diagnosis via Transformer-Enhanced U-Net Architecture.
Publication date: Jul 07, 2026 The substantia nigra pars compacta (SNpc) provides critical imaging biomarkers ... -
DTI-ALPS index correlates with poor neuromodulation outcomes of bilateral STN-DBS in Parkinson’s disease patients: a prospective cohort study.
Publication date: Jul 07, 2026 This prospective study evaluated whether preoperative glymphatic magnetic resonance imaging ... -
Cryo-EM structure of soluble VPS13C suggests its regulation by a conformational switch and by calmodulin.
Publication date: Jul 07, 2026 Bridge-like lipid transfer proteins (BLTPs) play fundamental roles in cellular ... -
Spontaneous aging of mature amyloids alters structural stability, cytotoxicity, and susceptibility to biological clearance.
Publication date: Jul 07, 2026 Accumulation of amyloid fibrils is a key factor in the ... -
Cardiovascular and neuropsychiatric outcomes with PCSK9 inhibitors in atherosclerotic cardiovascular disease: A retrospective cohort study.
Publication date: Jul 07, 2026 PCSK9 inhibitors reduce major cardiovascular events in randomized trials of ... -
Biological sex differences in neurodegenerative diseases in Africa: a scoping review of evidence and research gaps.
Publication date: Jul 07, 2026 Biological sex is a well-established determinant of risk, progression, and ... -
Sex-specific gut microbiota and metabolite signatures in Parkinson’s disease: implications for personalized therapeutics.
Publication date: Jul 07, 2026 Parkinson’s disease (PD) is characterized by dopaminergic neuron loss and ... -
Inhaled Levodopa for the Management of OFF Episodes in Patients with Parkinson’s Disease: A Network Meta-analysis.
Publication date: Jul 07, 2026 In the course of their disease, most patients with Parkinson’s ... -
Iron dyshomeostasis and enhanced myelination in the prefrontal cortex and ventral basal ganglia of a DJ-1 knockout model of early-onset Parkinson’s disease.
Publication date: Jul 07, 2026 Early-onset Parkinson’s disease (EOPD) differs from late-onset PD in clinical ... -
Long-lasting concordance between imaging-guided and clinical-based STN-DBS programming enhances motor and axial outcomes in Parkinson’s disease: A 3-year single-center study.
Publication date: Jul 07, 2026 Concepts Keywords axial symptoms deep brain stimulation directional stimulation image-guided ... -
Kynurenic Acid, a Key Endogenous Neuroprotective Agent: Role of Its Derivatives in Therapeutics.
Publication date: Jul 07, 2026 Kynurenic acid (KYNA) is an endogenous molecule that acts as ... -
Empowering clinical trial design with agentic intelligence and real-world data.
Publication date: Jul 07, 2026 Clinical trial design (CTD) is a time-consuming process that requires ... -
Transthyretin at the crossroads of neurodegeneration: a silent guardian in Parkinson’s disease.
Publication date: Jul 07, 2026 Parkinson’s disease (PD) is a progressive neurodegenerative disease characterised by ...